J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

US stocks fell as President Trump's rapid trade policy shifts kept investors on edge ahead of the next batch of corporate ...

U.S. stock futures were little changed Tuesday after two back-to-back days of gains on cautious tariff optimism.

Johnson & Johnson maintained its full-year 2025 adjusted earnings outlook of $10.50 to $10.70 a share, or 6.2% growth from a year ago at the midpoint.

The House of Representatives went on recess without acting on a measure to avert a possible billion-dollar budget cut in ...

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson & Johnson CEO Joaquin Duato said.

In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.

Bank of America (NYSE: BAC) and Citigroup (NYSE: C) continue the banking theme Tuesday, and are likely to benefit from the tariff-driven volatility in financial markets which has tended to boost ...